Gilead Sciences (NASDAQ: GILD) plans to present data from multiple HIV clinical trials at the 26th International AIDS Conference in Rio de Janeiro, Brazil, running July 26–31, according to a company statement.

Key presentations include long-term follow-up data from the open-label extension phases of the Phase 3 PURPOSE 1 and PURPOSE 2 trials evaluating twice-yearly lenacapavir as pre-exposure prophylaxis (PrEP). The data cover more than 7,178 person-years of follow-up in PURPOSE 1 and 5,295 in PURPOSE 2. In the PURPOSE 1 extension, no new HIV infections were observed among participants receiving lenacapavir. In PURPOSE 2, one infection was recorded among those continuing on lenacapavir, and none among those who switched from daily oral PrEP. Injection adherence was 96% in PURPOSE 1 and 92% in PURPOSE 2 through 52 weeks. No new safety signals were identified.

Gilead and Merck (NYSE: MRK) will also present full Phase 3 results from the ISLEND-1 and ISLEND-2 trials evaluating a once-weekly oral combination of islatravir and lenacapavir for HIV treatment. The combination is investigational and not approved for use. These results build on positive topline data announced in June.

Additional data include Week 104 outcomes from a Phase 2 study of lenacapavir combined with broadly neutralizing antibodies teropavimab and zinlirvimab, five-year results for Biktarvy in pediatric patients, and resistance profile data for investigational integrase inhibitor GS-3242.

On access, Gilead said it has expanded its no-profit supply program for lenacapavir PrEP from a planned reach of 2 million to up to 3 million people through 2028, in partnership with PEPFAR and the Global Fund. Lenacapavir is currently available in 10 priority countries in sub-Saharan Africa. The company said it is also in discussions with the Pan American Health Organization to explore access pathways in Latin America.